Washington University School of Medicine
Brendan Lucey
The purpose of this study is to determine if treatment with the sleep aid suvorexant can decrease the rate of amyloid-β (Aβ) accumulation in the brain.
Sleep
Alzheimer Disease
Suvorexant 20 mg
Placebo
PHASE2
This study will investigate if long-term treatment with suvorexant will slow amyloid-β accumulation in the brain. Amyloid-β is a protein involved in the disease process leading to Alzheimer's disease. This study will evaluate if suvorexant can decrease the amount of amyloid-beta detected by plasma pT217/T217.
Study Type : | INTERVENTIONAL |
Estimated Enrollment : | 200 participants |
Masking : | QUADRUPLE |
Primary Purpose : | PREVENTION |
Official Title : | Sleep Trial to Prevent Alzheimer's Disease |
Actual Study Start Date : | 2022-05-25 |
Estimated Primary Completion Date : | 2026-05 |
Estimated Study Completion Date : | 2026-05 |
Information not available for Arms and Intervention/treatment
Ages Eligible for Study: | 65 Years |
Sexes Eligible for Study: | ALL |
Accepts Healthy Volunteers: | 1 |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
RECRUITING
Washington University School of Medicine
St. Louis, Missouri, United States, 63110